focus -WSS

focus

author：leisure time 2025-08-11 08:01:27 - browse：7

There’s a specter haunting Wall Street.

It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on the assumption that GLP-1 weight loss treatments would cut them out of the market. Then the Ozempic panic came for dialysis firms, whose stocks fell about 20% in a single day on the news that Novo Nordisk’s medicine had delayed the progression of kidney disease in a study enrolling people with type 2 diabetes.

Now analysts from every sector are cranking out research notes on the disparate, dramatic, and often debatable implications of GLP-1 drugs’ growing popularity, said Jared Holz, a health care specialist at Mizuho Securities. Buy Bumble, sell McDonald’s. Short Pepsi, go long Louis Vuitton. Put your money in sectors that cater to a svelte and sated brand of consumer, and get out of the ones that rely on excess and compulsion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Why palliative psychiatry is worth discussing

hotspot

WSS

A new nitrogen execution bill also undermines medical licensing

A new nitrogen execution bill also undermines medical licensing

What to watch for from Zogenix and Amicus clinical trials

CDC Director Mandy Cohen on transparency, trust, and health

Truvian presents data for its desktop blood

Roche’s Alnylam deal shows drug firms interested in heart drugs

explore

focus

Wikipedia

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Hollywood unions extend contract negotiations for actors

Device maker Teleflex to acquire urology company for $600M

Hollywood unions extend contract negotiations for actors

What to watch for from Zogenix and Amicus clinical trials

Jerome Adams on the need for new antivirals for Covid

Biogen says it will cut costs by $700 million, slash 1,000 jobs

United colonoscopy coverage change 'may cost lives,' doctors say

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

focus

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

A solution to the after

PBM reform efforts get punted in Congress

Ed Silverman on new gene therapies, biosimilars, coffee, and more

PBM reform efforts get punted in Congress

PBM reform efforts get punted in Congress

hotspot

hotspot

entertainment

leisure time